ClouDr Group Limited released unaudited results for the six months ended 30 June 2026, highlighting a sharp improvement in profitability despite lower revenue.

Revenue and Profitability • Revenue fell 29.5% year-on-year to RMB 629.23 million, reflecting volume-based procurement pressure and the phase-out of low-margin businesses. • Gross profit slipped 11.3% to RMB 293.74 million, yet gross margin widened to 46.7% from 37.1% a year earlier, driven by a heavier mix of high-margin subscription and P2M offerings. • Operating loss narrowed to RMB 19.64 million from RMB 587.95 million; net loss contracted 94.3% to RMB 36.95 million. • Adjusted net loss (non-IFRS) improved to RMB 8.86 million versus RMB 63.40 million.

Segment Performance In-hospital Solution – Revenue: RMB 456.40 million (-29.8%). – Gross margin: 44.7% (up 9.6 ppts). • Value-added: RMB 243.86 million, margin 22.4%. • Subscription (targeted marketing): RMB 84.26 million, margin 97.9%. • P2M: RMB 128.28 million, margin 52.1%.

Out-of-hospital Solution – Revenue: RMB 172.83 million (-28.8%). – Gross margin: 51.9% (up 9.6 ppts). • Subscription: RMB 38.80 million, margin 93.2%. • Value-added: RMB 65.20 million, margin 21.3%. • P2M: RMB 33.41 million, margin 66.1%. • Others: RMB 35.43 million, margin 49.6%.

Operational Metrics • Hospitals connected: 15,266 (-3.6%), with Class III hospitals up 49.8%. • Pharmacies using ClouDr Pharmacy: 280,325 (+4.1%), covering c.40% of national total. • Registered users: 72.1 million (+43.6%). • Online prescriptions: 177.3 million (flat).

Cash & Balance Sheet • Cash and cash equivalents: RMB 240.52 million; time deposits and short-term investments: RMB 84.99 million. • Bank loans: RMB 196.00 million, all due within one year. • Gearing ratio: 46.8% (31 Dec 2025: 51.1%). • No interim dividend was declared.

Strategy and Outlook Management will continue prioritising high-margin, cash-generative growth, expand the P2M product pipeline, deepen AI model development, and enhance both hospital and pharmacy networks. The company sees its AI-driven platforms and extensive coverage as the foundation for further monetisation in chronic-disease management.